Premium
Prognosis and severity of myelin oligodendrocyte glycoprotein‐immunoglobulin G‐related diseases
Author(s) -
Nakashima Ichiro
Publication year - 2017
Publication title -
clinical and experimental neuroimmunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.297
H-Index - 15
ISSN - 1759-1961
DOI - 10.1111/cen3.12385
Subject(s) - myelin oligodendrocyte glycoprotein , neuromyelitis optica , multiple sclerosis , oligodendrocyte , demyelinating disease , myelin , antibody , immunology , demyelinating disorder , medicine , myelin associated glycoprotein , glycoprotein , immunoglobulin g , spectrum disorder , biology , central nervous system , microbiology and biotechnology , experimental autoimmune encephalomyelitis , psychiatry
Myelin oligodendrocyte glycoprotein‐immunoglobulin G‐related demyelinating disease is part of a relatively new disease spectrum that differs from multiple sclerosis. A recent European study showed that adult onset myelin oligodendrocyte glycoprotein‐immunoglobulin G‐related demyelinating disease might have frequent relapses and a poor prognosis similar to anti‐aquaporin 4 antibody‐positive neuromyelitis optica spectrum disorders.